References of "Drion, V"
     in
Bookmark and Share    
See detailUtilisation des antibiotiques dans la maladie de Crohn : de la théorie à la pratique
Louis, Edouard ULg; Drion, V.; Belaiche, Jacques ULg

in Médecine et Hygiène (1996), 54

Detailed reference viewed: 23 (0 ULg)
Full Text
Peer Reviewed
See detailIncreased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease.
Louis, Edouard ULg; Louis, Renaud ULg; Drion, V. et al

in Allergy (1995), 50(9), 729-33

Although bronchopulmonary manifestations are rare in inflammatory bowel disease (IBD), subclinical abnormalities have been described in up to 50% of cases. The pathophysiology of these abnormalities ... [more ▼]

Although bronchopulmonary manifestations are rare in inflammatory bowel disease (IBD), subclinical abnormalities have been described in up to 50% of cases. The pathophysiology of these abnormalities remains unknown. However, a latent inflammation of the bronchial mucosa secondary to the inflammation of the intestinal mucosa has been suggested. This subclinical inflammation may lead to increased bronchial responsiveness. We studied the bronchial responsiveness in 38 inflammatory bowel disease (IBD) patients, using the methacholine test. Bronchial hyperresponsiveness was defined by a PC20M < 16 mg/ml. Twenty-four healthy controls were also studied. There was no significant difference in baseline FEV1 between IBD patients and controls. However, there was a significantly greater fall in FEV1 in the IBD patients at the concentrations of methacholine tested. The frequency of bronchial hyperresponsiveness was significantly higher in the IBD population (45%) than in controls (17%; P < 0.03). Atopy, defined by skin test, was more common in IBD patients (42%) than in controls (21%). Even when only nonatopic subjects were considered, the frequency of bronchial hyperresponsiveness was significantly higher in IBD patients (41%) than in controls (5%; P < 0.02). Thus, subclinical bronchial hyperresponsiveness is common in IBD, and may be considered a further extraintestinal manifestation. [less ▲]

Detailed reference viewed: 31 (3 ULg)